Cargando…

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication

Tegoprazan, a novel potassium-competitive acid blocker, is currently available for the treatment of Helicobacter pylori infection. We compared the efficacies of tegoprazan-based triple and concomitant therapies in a real-world practice. Data of patients treated with a 14-day tegoprazan-based triple...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Chan Hyuk, Song, Myung Jin, Jung, Byung Wook, Park, Jung Ho, Jung, Yoon Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695183/
https://www.ncbi.nlm.nih.gov/pubmed/36422094
http://dx.doi.org/10.3390/jpm12111918
_version_ 1784837992546828288
author Park, Chan Hyuk
Song, Myung Jin
Jung, Byung Wook
Park, Jung Ho
Jung, Yoon Suk
author_facet Park, Chan Hyuk
Song, Myung Jin
Jung, Byung Wook
Park, Jung Ho
Jung, Yoon Suk
author_sort Park, Chan Hyuk
collection PubMed
description Tegoprazan, a novel potassium-competitive acid blocker, is currently available for the treatment of Helicobacter pylori infection. We compared the efficacies of tegoprazan-based triple and concomitant therapies in a real-world practice. Data of patients treated with a 14-day tegoprazan-based triple therapy (50 mg of tegoprazan + 1000 mg of amoxicillin + 500 mg of clarithromycin twice daily) or 10-day tegoprazan-based concomitant therapy (50 mg of tegoprazan + 1000 mg of amoxicillin + 500 mg of clarithromycin + 500 mg of metronidazole twice daily) were retrospectively reviewed. Primary endpoint was eradication rate in the intention-to-treat (ITT) population. Of the 928 included patients, 551 and 377 were treated with triple and concomitant therapies, respectively. Eradication rate from ITT analysis was 76.4% (95% confidence interval [CI], 72.7–79.8%) in the triple therapy group and 85.9% (95% CI, 82.2–89.2%) in the concomitant therapy group (p < 0.001). Eradication rate in the per-protocol analysis was also higher in the concomitant therapy group than in the triple therapy group (triple vs. concomitant therapy: 84.5% [81.1–87.5%] vs. 91.1% [87.8–93.8%]). Overall adverse event rate was 29.0% in the triple therapy group and 45.9% in the concomitant therapy group (p < 0.001). Adherence rate was similar between the two groups (triple vs. concomitant therapy: 90.0 vs. 92.6%, p = 0.180). Overall, the 10-day tegoprazan-based concomitant therapy had superior efficacy than the 14-day tegoprazan-based triple therapy for H. pylori eradication. Although concomitant therapy showed common adverse events, adherence was comparable between the two therapies.
format Online
Article
Text
id pubmed-9695183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96951832022-11-26 Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication Park, Chan Hyuk Song, Myung Jin Jung, Byung Wook Park, Jung Ho Jung, Yoon Suk J Pers Med Article Tegoprazan, a novel potassium-competitive acid blocker, is currently available for the treatment of Helicobacter pylori infection. We compared the efficacies of tegoprazan-based triple and concomitant therapies in a real-world practice. Data of patients treated with a 14-day tegoprazan-based triple therapy (50 mg of tegoprazan + 1000 mg of amoxicillin + 500 mg of clarithromycin twice daily) or 10-day tegoprazan-based concomitant therapy (50 mg of tegoprazan + 1000 mg of amoxicillin + 500 mg of clarithromycin + 500 mg of metronidazole twice daily) were retrospectively reviewed. Primary endpoint was eradication rate in the intention-to-treat (ITT) population. Of the 928 included patients, 551 and 377 were treated with triple and concomitant therapies, respectively. Eradication rate from ITT analysis was 76.4% (95% confidence interval [CI], 72.7–79.8%) in the triple therapy group and 85.9% (95% CI, 82.2–89.2%) in the concomitant therapy group (p < 0.001). Eradication rate in the per-protocol analysis was also higher in the concomitant therapy group than in the triple therapy group (triple vs. concomitant therapy: 84.5% [81.1–87.5%] vs. 91.1% [87.8–93.8%]). Overall adverse event rate was 29.0% in the triple therapy group and 45.9% in the concomitant therapy group (p < 0.001). Adherence rate was similar between the two groups (triple vs. concomitant therapy: 90.0 vs. 92.6%, p = 0.180). Overall, the 10-day tegoprazan-based concomitant therapy had superior efficacy than the 14-day tegoprazan-based triple therapy for H. pylori eradication. Although concomitant therapy showed common adverse events, adherence was comparable between the two therapies. MDPI 2022-11-17 /pmc/articles/PMC9695183/ /pubmed/36422094 http://dx.doi.org/10.3390/jpm12111918 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Park, Chan Hyuk
Song, Myung Jin
Jung, Byung Wook
Park, Jung Ho
Jung, Yoon Suk
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
title Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
title_full Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
title_fullStr Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
title_full_unstemmed Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
title_short Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
title_sort comparative efficacy of 14-day tegoprazan-based triple vs. 10-day tegoprazan-based concomitant therapy for helicobacter pylori eradication
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695183/
https://www.ncbi.nlm.nih.gov/pubmed/36422094
http://dx.doi.org/10.3390/jpm12111918
work_keys_str_mv AT parkchanhyuk comparativeefficacyof14daytegoprazanbasedtriplevs10daytegoprazanbasedconcomitanttherapyforhelicobacterpylorieradication
AT songmyungjin comparativeefficacyof14daytegoprazanbasedtriplevs10daytegoprazanbasedconcomitanttherapyforhelicobacterpylorieradication
AT jungbyungwook comparativeefficacyof14daytegoprazanbasedtriplevs10daytegoprazanbasedconcomitanttherapyforhelicobacterpylorieradication
AT parkjungho comparativeefficacyof14daytegoprazanbasedtriplevs10daytegoprazanbasedconcomitanttherapyforhelicobacterpylorieradication
AT jungyoonsuk comparativeefficacyof14daytegoprazanbasedtriplevs10daytegoprazanbasedconcomitanttherapyforhelicobacterpylorieradication